pentobarbital will lessen the level or outcome of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic influence of elbasvir/grazoprevir may very well be minimized if coadministered with strong CYP3A inducers and is as a result contraindicated.pentobarbital will lessen the level or impact o